IMNN
Imunon, Inc. NASDAQ Listed Mar 1, 1999$2.73
Mkt Cap $6.9M
52w Low $2.52
0.5% of range
52w High $41.22
50d MA $3.01
200d MA $4.29
P/E (TTM)
-0.4x
EV/EBITDA
-0.0x
P/B
0.8x
Debt/Equity
0.1x
ROE
-205.3%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
2.12
50d MA
$3.01
200d MA
$4.29
Avg Volume
90.3K
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
997 Lenox Drive · Lawrenceville, NJ 08648 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -1.43 | -1.29 | +9.8% | 2.94 | -1.0% | +1.7% | +9.5% | +6.8% | +6.1% | +6.5% | — |
| Nov 13, 2025 | AMC | -1.73 | -1.16 | +32.9% | 4.16 | -6.0% | +1.4% | -4.1% | -1.7% | -9.1% | -11.3% | — |
| Aug 5, 2025 | AMC | -3.09 | -1.87 | +39.5% | 7.62 | -12.3% | -18.5% | -8.8% | -5.8% | -7.1% | -10.2% | — |
| May 12, 2025 | AMC | -4.56 | -3.65 | +20.0% | 12.24 | -9.2% | -2.0% | -24.9% | -31.2% | -40.7% | -42.4% | — |
| Feb 27, 2025 | AMC | -0.36 | -0.23 | +36.1% | 12.15 | +0.0% | +10.0% | +7.8% | +4.4% | +8.6% | +9.9% | — |
| Nov 7, 2024 | AMC | -0.37 | -0.34 | +8.1% | 12.32 | -0.6% | -2.6% | +0.9% | -5.6% | -9.1% | -8.9% | — |
| Aug 14, 2024 | AMC | -0.55 | -0.51 | +7.3% | 14.35 | +0.3% | +4.5% | +19.2% | +26.5% | +29.6% | +38.0% | — |
| May 13, 2024 | AMC | -0.57 | -0.52 | +8.8% | 22.20 | +4.1% | -8.8% | -4.7% | -5.4% | -5.4% | -7.4% | — |
| Mar 28, 2024 | AMC | -0.59 | -0.52 | +11.9% | 24.60 | +1.8% | +17.7% | +6.7% | -15.2% | -15.2% | -0.6% | — |
| Nov 14, 2023 | AMC | -0.66 | -0.37 | +43.9% | 14.25 | +2.1% | +2.0% | -1.5% | +0.6% | -2.1% | -5.7% | — |
| Aug 10, 2023 | AMC | -0.71 | -0.61 | +14.1% | 18.15 | -0.8% | -4.1% | -2.5% | -2.5% | -2.5% | -5.8% | — |
| May 11, 2023 | AMC | -0.69 | -0.68 | +1.4% | 19.20 | +2.3% | +2.3% | +5.2% | -1.6% | +3.1% | +7.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | D. Boral Capital | Downgrade | Buy → Hold | — | $7.26 | $7.50 | +3.3% | -2.9% | -8.5% | -17.5% | -14.2% | +139.7% |
| May 13 | D. Boral Capital | Maintains | Buy → Buy | — | $12.24 | $11.12 | -9.2% | -2.0% | -24.9% | -31.2% | -40.7% | -42.4% |
| May 7 | D. Boral Capital | Maintains | Buy → Buy | — | $12.45 | $12.08 | -3.0% | -1.2% | +0.6% | -3.6% | -1.7% | -3.6% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.00 | $15.00 | +0.0% | +4.0% | +14.0% | +9.0% | +5.0% | +6.0% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $14.25 | $14.25 | +0.0% | +12.6% | +5.3% | +9.5% | +20.0% | +14.7% |
| Feb 27 | D. Boral Capital | Maintains | Buy → Buy | — | $12.07 | $12.15 | +0.7% | +0.7% | +10.7% | +8.5% | +5.1% | +9.4% |
| Feb 19 | D. Boral Capital | Maintains | Buy → Buy | — | $12.93 | $12.75 | -1.4% | +2.7% | +1.2% | +6.7% | +0.0% | -3.6% |
| Jan 24 | D. Boral Capital | Maintains | Buy → Buy | — | $14.36 | $15.15 | +5.5% | +0.1% | -2.2% | -4.6% | -5.9% | -4.9% |
| Dec 19 | D. Boral Capital | Maintains | Buy → Buy | — | $12.46 | $12.57 | +0.9% | +2.8% | -0.1% | -4.8% | -1.8% | -4.9% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.46 | $12.57 | +0.9% | +2.8% | -0.1% | -4.8% | -1.8% | -4.9% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.49 | $13.18 | -2.3% | -6.6% | -5.5% | -6.1% | -6.6% | -3.6% |
| Dec 10 | D. Boral Capital | Maintains | Buy → Buy | — | $12.90 | $12.75 | -1.2% | +4.6% | -2.3% | -1.2% | -1.8% | -2.3% |
| Nov 25 | D. Boral Capital | Maintains | Buy → Buy | — | $12.18 | $12.60 | +3.4% | +0.2% | +2.1% | +5.4% | +3.9% | +6.6% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.00 | $12.45 | +3.8% | +3.6% | -3.1% | -6.7% | -6.5% | -9.9% |
| Nov 7 | EF Hutton | Maintains | Buy → Buy | — | $14.06 | $14.10 | +0.3% | -12.4% | -14.7% | -11.6% | -17.3% | -20.3% |
| Oct 31 | EF Hutton | Maintains | Buy → Buy | — | $14.40 | $14.33 | -0.5% | -3.1% | -1.0% | +2.1% | +2.1% | -2.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.35 | $14.40 | +0.3% | +4.5% | +19.2% | +26.5% | +29.6% | +38.0% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.95 | $16.65 | -1.8% | +8.0% | +2.7% | -5.3% | -0.9% | -3.5% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.20 | $23.10 | +4.1% | -8.8% | -4.7% | -5.4% | -5.4% | -7.4% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.60 | $25.05 | +1.8% | +17.7% | +6.7% | -15.2% | -15.2% | -0.6% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.95 | $13.65 | -2.2% | -6.3% | -14.0% | -7.5% | -11.3% | -13.3% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.10 | $16.80 | -1.8% | +3.5% | +2.6% | -1.8% | -4.4% | -6.1% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.15 | $18.00 | -0.8% | -4.1% | -2.5% | -2.5% | -2.5% | -5.8% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.20 | $19.65 | +2.3% | +2.3% | +5.2% | -1.6% | +3.1% | +7.0% |
| Oct 13 | Alliance Global Partners | Maintains | Buy → Buy | — | $22.65 | $23.25 | +2.6% | -0.7% | -0.7% | +4.0% | +3.3% | +1.3% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.20 | $53.55 | +2.6% | +4.6% | +0.6% | -4.3% | -3.4% | -2.6% |
No insider trades available.
8-K · 5.02
!!! Very High
Imunon, Inc. -- 8-K 5.02: Executive Change
Imunon's executive departure triggers change-in-control severance benefits including health and life insurance continuation for up to eighteen months, indicating potential leadership transition or company restructuring.
May 4
8-K
Unknown — 8-K Filing
Immunation Holdings' 8-K indicates late-stage immunotherapy development progress, suggesting potential upcoming clinical milestones that could materially impact valuation if successful.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Imunon is activating an at-the-market offering to raise capital, allowing potential dilution but providing financial flexibility for operations and development.
Mar 23
8-K · 5.02
!!! Very High
Imunon, Inc. -- 8-K 5.02: Executive Change
Imunon's Chief Scientific Officer Khursheed Anwer is retiring effective February 20, 2026, potentially affecting the company's research direction and scientific credibility during critical development phases.
Feb 5
Data updated apr 25, 2026 3:19pm
· Source: massive.com